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HigH-risk Human PaPillomavirus Positive lung CanCer: 
moleCular evidenCe for a Pattern of Pulmonary 
metastasis
High-risk type human papillomavirus (hrHPV) infection is associated with several 
cancers, for instance cervical and oropharyngeal cancers, whereas it’s causal relationship 
with lung cancer is controversial. van Boerdonk et al. therefore investigated the role of 
hrHPV in lung cancer development in specimens from 223 Dutch patients. Archived tis-
sue specimens used consisted of primary lung carcinomas of patients without a history of 
prior cancer, primary lung carcinomas of patients with a history of an unrelated cancer, 
and carcinomas with primary presentation in the lungs of equivocal origins at time of 
diagnosis. Consensus primer hrHPV DNA PCR (GP5+/6+-PCR) and p16INK4a –immuno-
histochemistry were used to identify GP5+/6+-PCR/p16INK4A-double-positive carcino-
mas. These were further assessed by HPV genotyping, HPVE7 transcript analysis, loss 
of heterozygosity analysis, and array comparative genomic hybridization. The findings 
revealed no link of hrHPV infection to the development of primary lung cancer. However, 
the presence of hrHPV in 25% of equivocal carcinomas from patients with a history of 
hrHPV-associated disease suggested pulmonary metastasis from a primary cancer bearing 
hrHPV in other sites of the body. The evidence implies metastatic disease when a hrHPV-
positive cancer is detected in the lungs, which is clinically significant in differentiation 
between primary cancer and metastatic disease in lungs, the most common site of metas-
tasis of solid tumors. 
Van Boerdonk RAA, Daniels JMA, Bloemena E, et al. High-risk human papilloma-
virus positive lung cancer: molecular evidence for a pattern of pulmonary metastasis. J 
Thorac Oncol 2013;8:711-718.
niCotine induCes resistanCe to ePidermal growtH faCtor 
reCePtor tyrosine kinase inHibitor by Œ±1 niCotiniC 
aCetylCHoline reCePtor-mediated aCtivation in PC9 Cells
Nicotine binds to nicotinic acetylcholine receptors (nAChRs) on non-small cell lung 
cancer (NSCLC) cells and has been shown to regulate cell proliferation, angiogenesis, and 
resistance to apoptosis. It has also been demonstrated to affect the effectiveness of cancer 
therapy, but the mechanism involved is unclear. Previous study suggested a few α-subunits 
of nAChRs to play a role in nicotine-induced lung cancer. In this study, the authors focused 
on α1 nAChR. They assessed the expression of its mRNA and protein in several human 
NSCLC cell lines and tissues. They also investigated the role of nicotine in the activation 
of ERK and AKT pathways via α1 nAChR, and the effect of nicotine-α1 nAChR signaling 
on the difference of anti-cancer effect of epidermal growth factor receptor tyrosine kinase 
inhibitor (EGFR-TKI) in active smokers with smoking-related lung cancer and in never 
smokers. The findings revealed a novel pathway of nicotine-stimulated survival mediated 
by α1 nAChR via EGFR phosphorylation in PC9 cells. Resistance to EGFR-TKI was found 
to be enhanced by continued or chronic exposure to nicotine, mediated by α1 nAChR in 
PC9 cells. Silencing of the receptor subunit was shown to potentially overcome nicotine-
induced resistance to EGFR-TKI. Together, the findings support the role of nicotine in lung 
cancer development, and the potential role of α1 nAChR as a biomarker for EGFR-TKI 
therapy or a novel therapeutic target for NSCLC. This study also raises concern about the 
safety of nicotine replacement therapy due to the role of α1 nAChR in lung carcinogenesis, 
and further supports smoking cessation in the prevention of nicotine-induced EGFR-TKI 
resistance in smoking cancer patients. 
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Wang S, Takayama K, Tanaka K, et al. Nicotine induces resistance to epidermal 
growth factor receptor tyrosine kinase inhibitor by Œ±1 nicotinic acetylcholine receptor-
mediated activation in PC9 cells. J Thorac Oncol 2013;8:719-725.
PolymorPHisms in mtorC1 genes modulate risk of 
esoPHageal squamous Cell CarCinoma in eastern CHinese 
PoPulations
Mammalian target of rapamycin complex 1 (mTORC1) pathway plays an impor-
tant role in regulating cellular functions, so functional single nucleotide polymorphisms 
(SNPs) of mTORC1 genes are likely to affect cancer risk. But the associations between 
these SNPs and risk of esophageal squamous cell carcinoma (ESCC) are yet to be explored. 
The authors therefore genotyped eight potential functional SNPs of the mTORC1 genes 
(mTOR rs1883965 G>A and rs2536 T>C, mLST8 rs3160 C>T and rs26865 G>A, Raptor 
rs3751934 C>A, rs1062935 T>C, rs3751932 T>C and rs12602885 G>A) and evaluate their 
associations with risk of ESCC in a Chinese population of 1126 ESCC patients and 1131 
cancer-free controls. In the single locus analyses, mTOR rs1883965 A variant genotypes 
were individually associated with an increased ESCC risk. When all eight SNPs were com-
bined, risk of ESCC increased with individuals bearing two or more unfavorable genotypes 
as compared with those bearing less than two unfavorable genotypes. This was a dose-
dependent effect. Findings from the multiple dimension reduction (MDR) analysis also 
identified mTOR rs1883965 to be the strongest individual factor for ESCC risk. Moreover, 
the model that combines all studied SNPs is the best model in ESCC risk prediction in this 
population (lowest prediction error of 17.66%). The results of this study suggest that func-
tional SNPs of mTORC1 genes could individually or collectively affect the risk of ESCC 
and further studies are warranted to confirm these findings. 
Zhu ML, Yu H, Shi TY, et al. Polymorphisms in mTORC1 genes modulate risk of 
Esophageal Squamous Cell Carcinoma in Eastern Chinese populations. J Thorac Oncol 
2013;8:788-795.
Research Watch
a ProPensity sCore-matCHed analysis of stereotaCtiC 
ablative radiotHeraPy (sabr) versus lobeCtomy by video-
assisted tHoraCosCoPiC surgery (vats) in stage i–ii non-
small-Cell lung CanCer 
Video-assisted thoracoscopic surgery (VATS) lobectomy and stereotactic ablative 
radiotherapy (SABR) are both used to treat early-stage non-small-cell lung cancer (NSCLC). 
The former is minimally invasive with reduced morbidity and shorter hospital stays while 
the latter is preferred when patients are deemed not suitable for surgery. This study aimed 
to compare the treatment outcomes using VATS lobectomy and SABR by assessing locore-
gional control (LRC) after both treatments in patients with clinical stage I-II NSCLC. The 
retrospective analysis matched 64 VATS and 64 SABR patients using propensity scores 
based on cTNM stage, age, gender, Charlson comorbidity score, lung function and perfor-
mance score. Locoregional failure was defined as recurrence in/adjacent to the planning 
target volume/surgical margins, ipsilateral hilum or mediastinum. Recurrences were con-
firmed by biopsy or PET-positive and reviewed by a tumor board. The findings identified 
SABR treatment as more superior (significant higher LRC rates and lower toxicity profile) 
to VATS lobectomy, although no significant difference in overall survival was found. The 
results support further studies in randomized, controlled trials to compare the two treatment 
modalities, and to evaluate the role of SABR as a treatment option for medically operable 
stage I NSCLC patients. 
Verstegen NE, Oosterhuis JWA, Palma DA, et al. Stage I–II non-small-cell lung 
cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by 
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video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched 
analysis. Ann Oncol doi:10.1093/annonc/mdt026 (2013).
a CanCer stem Cell model for studying brain metastases 
from Primary lung CanCer 
Previously developed primary solid tumor-initiating cell models were used to assess 
the presence of a cancer stem cell population in brain metastases from the lung. The authors 
demonstrated for the first time the presence of a stem-like population in brain metasta-
ses from the lung. NCI-H1915 cells grown in stem-enriching cNSC conditions were also 
shown to be an appropriate model for the study of stem cell population in brain metastases, 
and could be used to assess the effects of new therapeutics on self-renewal or tumor growth. 
Several genes overexpressed in brain metastases were also identified in this study to be sig-
nificant predictors of poor survival in primary lung cancer. These genes, which could play 
important roles in the metastatic stem cell population, could be potential therapeutic targets 
in interfering metastasis.  
Nolte SM, Venugopal C, McFarlane N, et al. A Cancer Stem Cell Model for Studying 
Brain Metastases From Primary Lung Cancer. J Nat Cancer Institute doi:10.1093/jnci/
djt022 (2013).
myC inHibition eradiCates kras-driven lung tumors in vivo 
The authors previously demonstrated in a preclinical mouse model of non-small-
cell lung cancer that systemic inhibition of Myc using the dominant-negative Myc mutant 
Omomyc exerts a dramatic therapeutic impact, causing rapid regression of KRasG12D-driven 
lung tumors within 3 days, and all animals were tumor-free by 1 week of sustained Myc 
inhibition. Side effects were mild and completely reversible by restoring Myc function. 
Using protracted episodic expression of Omomyc, this study now demonstrated that met-
ronomic Myc inhibition contains Ras-driven lung tumors indefinitely, and leads to their 
progressive eradication. Although transient inhibition of Myc did not eradicate all tumors 
immediately, the effects of initial tumor regression and decrease of tumor multiplicity upon 
relapse dramatically extends overall survival of mice with lung tumors. No evidence of 
Omomyc refractory tumors was found, suggesting that lung tumors were unable to acquire 
or evolve resistance to Myc inhibition. The authors also showed the involvement of p53 
facilitating, but not essential for, the therapeutic impact of Myc inhibition. The findings 
from this study further support the fact that Myc is both essential and functionally non-
redundant for tumor maintenance, and its inhibition cannot be overcome by adaptive or 
evolutionary mechanism, even in aggressive p53-deficient tumors. Myc is therefore an 
attractive cancer drug target. 
Soucek L, Whitfield JR, Sodir NM, et al. Inhibition of Myc family proteins eradicates 
KRas-driven lung cancer in mice. Genes Dev 2013;27: 504-513.
moleCular CHaPerone HsP90 inHibitor is Potent against 
alk-Positive nsClC and taCkles Crizotinib resistanCe 
Patients with anaplastic lymphoma kinase (ALK)-positive NSCLC generally respond 
well to the ALK inhibitor, crizotinib but most patients eventually develop resistance to the 
drug. The Hsp90 inhibitor, ganetespib, had 30 times greater in vitro potency than crizo-
tinib, wiping out ALK protein expression. It also displayed greater antitumor activity in 
vivo and prolonged animal survival compared with crizotinib. When used in combination 
with other ALK targeting agents, ganetespib showed enhanced efficacy in vitro and in vivo. 
Importantly, the drug overcame multiple forms of resistance to crizotinib in ALK-positive 
NSCLC, which was observed in a patient with ALK-driven NSCLC following crizotinib 
therapy. Ganetespib is also effective against cancer cells bearing ALK amplification, ROS1 
and RET gene rearrangements. This study highlights a promising approach for treating 
ALK-positive NSCLC by targeting molecular chaperone Hsp90 with ganetespib, including 
those that are crizotinib-resistant. 
Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chap-
erone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer 
Discov doi:10.1158/2159-8290.cd-12-0440 (2013).
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News in Brief
fda grants novartis ComPound ldk378 witH 
breaktHrougH tHeraPy designation for alk+ non-small 
Cell lung CanCer 
LDK378 is an investigational selective inhibitor of anaplastic lymphoma kinase 
(ALK), which is found in 3% to 8% of metastatic non-small cell lung cancer (NSCLC). 
Limited treatment options are currently available for patients with ALK+ NSCLC, who 
tend to be nonsmokers and younger than NSCLC patients without an ALK translocation. 
The FDA granted LDK378 Breakthrough Therapy designation based on the early positive 
data for the treatment of ALK+ NSCLC patients who have progressed during treatment 
with crizotinib or were intolerant with crizotinib. Under Breakthrough Therapy designa-
tion, development and review is expedited for a drug that treats life-threatening conditions 
provided the treatment shows significant improvement compared to the standard therapy 
available. Initial data from Phase I studies demonstrated a response rate (including com-
plete response [CR], partial response [PR] and unconfirmed PR) of 80% in patients whose 
disease progressed after crizotinib therapy. First filing of the drug is planned in early 2014. 
tHe nation’s first “breatHing lung” transPlant 
A patient with pulmonary fibrosis received the nation’s first lung transplant using 
the “breathing lung” technology developed by TransMedics. The surgery was a success 
and the patient is now living a normal life. The “breathing lung” device is under the inter-
national, multicenter clinical trial, INSPIRE, which involves the United States, Europe, 
Australia, and Canada, to compare with the standard icebox method in donor lungs trans-
portation. This experimental device is a portable system that keeps donor lungs functioning 
and “breathing” in a near-physiologic state outside the body during transport to a recipient, 
instead of the standard method, in which the organs are kept in an icebox in a non-function-
ing, non-breathing state. The state of how the lung is functioning is also being monitored 
during the transport. This device could potentially improve the function of the donor lungs 
before transplant, allow better assessment of donor lungs over a longer period of time, and 
expand the donor pool across longer distance. 
CHinese women witH HigHer soy intake before lung CanCer 
diagnosis live longer 
A large observational follow-up study conducted in Shanghai, China with collab-
oration between the United States National Cancer Institute, Vanderbilt University, and 
Shanghai Cancer Institute was the first study to demonstrate an association between high 
soy intake before lung cancer diagnosis and better overall survival. The same research group 
has also recently showed that high soy food consumption was linked to a 40% decrease in 
lung cancer risk. Soy contains estrogen-like substances, isoflavones, which are known to 
impact tumor growth and development. Information on dietary soy food intake of study 
participants was collected at enrollment and 2 years later. Sixty percent of patients in the 
highest soy intake group (4 oz or more tofu per day) were alive 12 months after diagnosis 
compared to 50% in the lowest soy intake group (2 oz or less per day). The survival benefit 
levels off after more than 4 oz of tofu per day. Despite promising findings, dietary recom-
mendations to the public are still too early, according to the lead study author. The findings 
may also not be applicable beyond the study population, i.e., high prevalence of smoking 
and postmenopausal hormone replacement therapy use. Further study exploring the impact 
of soy intake after lung cancer diagnosis on survival, especially in patients with early stage 
lung cancer is warranted. 
aaCr seCond annual rePort on CanCer survivorsHiP in tHe 
united states 
The report published in Cancer Epidemiology, Biomarkers & Prevention illustrates 
that the number of cancer survivors in the United States (approximately 13.7 million in 
2012) is expected to increase by 31% (to 18 million) by 2022. Survival varied across cancer 
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types: women with breast cancer account for 22% of survivors currently, men with pros-
tate cancer constitute 20%, while lung cancer survivors account for only 3%. This clearly 
underscores the need for better diagnostic tools and treatment for lung cancer. 
aaCr 2013: PrevalenCe of benign disease diagnosis after 
lung surgery varied widely by state 
Although the NSLT findings showed that low-dose CT screening could reduce lung 
cancer deaths by 20% when compared with chest x-ray, the false positive rate was 96% 
and 24% of follow-up lung resections were negative for lung cancer. The prevalence of 
benign disease diagnosis after lung resection for suspected lung cancer, which could affect 
the outcome of screening, was not known. At the AACR Annual Meeting 2013, Deppen 
and colleagues discussed their findings on the prevalence of benign disease diagnosis rates 
by state, using the Medicare Provider Analysis and Review (MedPAR) Hospital National 
Limited Data Set from 2009. From 25,362 patients who underwent lung surgery for known 
or suspected lung cancer, 9.1% had a benign disease diagnosis after surgery, 2.3% died 
in the hospital after surgery, and 2.1% of  those who were found not to have lung cancer 
died. Benign disease diagnosis rates after surgery for suspected lung cancer varied widely 
by state (from 1.2% in Vermont to 25% in Hawaii). The higher benign disease prevalence 
after surgery may reduce the benefits of lung cancer screening observed in the NSLT. 
Determining the underlying causes for these variations by state could provide useful infor-
mation for health policy and clinical guidelines development for lung cancer screening. 
